Individualized dosing technique with multiple variables

A method of determining the effect of ingested compounds on the activity of an anti-coagulant drug in an individual human patient with a hypercoagulable condition and treatment thereof comprising:

• a) obtaining a blood sample from a human patient with a hypercoagulable condition;
• b) detecting an observed International Normalized Ratio (INR) for the human patient with the hypercoagulable condition;
• c) obtaining data of general information of the individual human patient with a hypercoagulable condition comprising:
• current average daily dose of an anti-coagulant drug in milligrams,
• percent compliance of taking the anti-coagulant drug,
• the individual human patient's weight,
• the individual human patient's temperature,
• number of episodes of fevers,
• number of episodes of diarrhea,
• kidney function,
• liver function,
• number of bleeding episodes since last visit, and
• number of clotting episodes since last visit;
• d) obtaining data concerning ingested compounds by the individual human patient with a hypercoagulable condition comprising:
• amount and type of alcohol ingested,
• current prescription drugs, including dosage, frequency and route of intake, and
• amount and type of Vitamin K containing food eaten, and any change in the intake of these foods,
• e) generating and assigning a regression coefficient ((3) for each data (x) in step c) and step d);
• wherein logistic function is
• Y
• =
• 1
• 1
• +
• e
• -
• z
• and wherein variable z represents the exposure to independent variables, variable Y represents the probability of a particular outcome, and variable z is defined as:
• z=βo+β1x1+β2x2+β3x3+ . . . +βnxn
• f) using each βnXn from step e) to represent a predicted relationship between dose amount of the anti-coagulant drug and a predicted INR between 2 and 3 in the individual human patient with a hypercoagulable condition;
• g) modifying each regression coefficient (βn) for each data (xn) until the mathematical model program generates an equation of a line representing the predicted relationship between the dose amount of the anti-coagulant drug and the predicted INR which corresponds to the observed INR in the individual human patient with a hypercoagulable condition;
• and
• h) administering a treatment to the human patient with the hypercoagulable condition, wherein the treatment is the dose amount of the anti-coagulant drug calculated from the equation of the line representing the relationship between the dose amount of the anti-coagulant drug and the predicted INR, and wherein the anti-coagulant drug is selected from the group consisting of Warfarin, Coumadin, Jantoven, Marevan, Lawarin, Waran, Warfant and heparin.